drugset
drugset / Trial / NCT03968848

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

NCT03968848 ↗

Phase 1 Completed 16 enrolled Acerta Pharma BV AstraZeneca · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.

Timeline

Start
2018-11-12
Primary completion
2019-03-13
Completion
2019-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 50 mg Oral

Indications

liver disorder